Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
|Articles|January 1, 2002
Oncology NEWS International
- Oncology NEWS International Vol 11 No 1
- Volume 11
- Issue 1
ONCC Certification Test Results Are Announced
PITTSBURGH-The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.
Advertisement
PITTSBURGHThe Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.
Of nearly 3,000 nurses who took the Oncology Certified Nurse (OCN) test, 2,503 (85%) passed, including 1,409 who were newly certified and 1,094 who renewed their credential.
More than 300 registered nurses took the Certified Pediatric Oncology Nurse (CPON) examination, and 244 (77%) passed, 150 who were newly certified and 94 who renewed their CPON certification.
Articles in this issue
almost 25 years ago
ODAC Sends Mixed Message on New Gliadel Wafer Indicationalmost 25 years ago
Rituximab Ups Survival in Aggressive and Indolent NHLalmost 25 years ago
Topotecan Used in Aggressive Front-Line Therapy for SCLCalmost 25 years ago
Depsipeptide Shows Activity in T-Cell Lymphomaalmost 25 years ago
FDG-PET Useful in Newly Diagnosed and Recurrent NSCLCalmost 25 years ago
Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trialalmost 25 years ago
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insertalmost 25 years ago
FDA and VA Plan Joint AIDS Studyalmost 25 years ago
Breast Conservation Increases With On-Site Radiation Unitalmost 25 years ago
Washington State Hikes Cigarette TaxAdvertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
FDA Grants Priority Review to Zanubrutinib Regimen in Frontline MCL
4
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
5